Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
O95455
UPID:
TGDS_HUMAN
Alternative names:
-
Alternative UPACC:
O95455; Q05DQ3; Q2TU31; Q5T3Z2; Q9H1T9
Background:
The protein dTDP-D-glucose 4,6-dehydratase, encoded by the gene with accession number O95455, plays a crucial role in the biosynthesis of dTDP-L-rhamnose, a sugar essential for the cell wall integrity in bacteria and plant cells. Its enzymatic activity is pivotal in converting dTDP-D-glucose into dTDP-4-keto-6-deoxy-D-glucose, a precursor in the synthesis of dTDP-L-rhamnose.
Therapeutic significance:
Understanding the role of dTDP-D-glucose 4,6-dehydratase could open doors to potential therapeutic strategies. Specifically, its involvement in Catel-Manzke syndrome, a genetic disorder characterized by unique skeletal abnormalities and cleft palate, highlights its potential as a target for therapeutic intervention. Developing inhibitors for this enzyme could offer a novel approach to treat this syndrome.